Loading...
Market
How many additional acquisitions will Mankind Pharma make by end of 2025?
2
Resolution / Starting Odds
No further acquisitions • 25%
One additional acquisition • 25%
Two additional acquisitions • 25%
Three or more additional acquisitions • 25%
Official announcements from Mankind Pharma, press releases, or financial news outlets
Story
Mankind Pharma Secures CCI Approval for ₹13,360 Crore Bharat Serums Acquisition
Oct 2, 2024, 02:01 AM
Mankind Pharma has received approval from the Competition Commission of India (CCI) for its acquisition of Bharat Serums and Vaccines Limited. The acquisition deal is valued at ₹13,360 crore (approximately $1.6 billion), though some reports indicate a value of Rs 13,630 crore. This transaction involves Mankind Pharma acquiring 100% shareholding of Bharat Serums and Vaccines Limited. Mankind Pharma is India's fourth-largest drug maker.
View original story
Similar markets
1 new acquisition • 25%
2 new acquisitions • 25%
3 new acquisitions • 25%
4 or more new acquisitions • 25%
No new launches • 25%
1-2 new launches • 25%
3-4 new launches • 25%
More than 4 new launches • 25%
More than 3 new drugs • 25%
2-3 new drugs • 25%
1 new drug • 25%
No new drugs • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
3 or more • 25%
2 • 25%
1 • 25%
None • 25%
Biotech company • 25%
Pharmaceutical company • 25%
Medical device company • 25%
Other • 25%
Less than 10 • 25%
10-20 • 25%
21-30 • 25%
More than 30 • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
1-2 projects • 25%
3-4 projects • 25%
5-6 projects • 25%
More than 6 projects • 25%
None • 25%
1 new category • 25%
2 to 3 new categories • 25%
More than 3 new categories • 25%